Valeant appoints William Humphries as EVP, dermatology
Mr. Humphries will join Valeant's Executive Committee. Mr. Humphries has nearly 30 years of experience in the dermatology and specialty pharmaceuticals industry.
He joins Valeant from Merz GmbH & Co. KGaA, where he most recently served as CEO of its North America business.
Prior to Merz, he served as President of Stiefel, a global dermatological pharmaceutical company, that is now a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan, Inc., including Vice President of the U.S. skincare business.
Rob Rosiello will also depart the Company on December 31, 2016.
Mr. Rosiello previously served as the Valeant CFO from July 2015 through August 2016 and has successfully transitioned the role to the new CFO, Paul Herendeen.
Dr. Ari Kellen, EVP & Company Group Chairman will also depart Valeant on December 31, 2016.
Dr. Kellen and Mr. Rosiello will continue to serve as consultants on an ongoing basis.